Peptide Initiative

Peptides · Peptide comparison

CJC-1295 (No DAC) vs Tabimorelin

A modified growth hormone-releasing hormone that boosts your body's natural GH pulses for better recovery, deeper sleep, and improved body composition [13] [17].

An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.

  • Growth Hormone
  • Growth Hormone

At a glance

Quick comparison

Dose rangeCJC-1295 (No DAC)100–100 mcgTabimorelin1.5–1.5 mg/kg
FrequencyCJC-1295 (No DAC)Once dailyTabimorelinOnce daily
AdministrationCJC-1295 (No DAC)Subcutaneous injectionTabimorelinOral (capsule or solution)
Cycle lengthCJC-1295 (No DAC)8-12 weeksTabimorelin4-6 weeks
Onset speedCJC-1295 (No DAC)Moderate (1-2 weeks)TabimorelinModerate (1-2 weeks)
Evidence levelCJC-1295 (No DAC)Moderate human trials (Phase 1-2)TabimorelinModerate human trials (Phase 1-2)

Efficacy

Benefit ratings

GH Stimulation

CJC-1295 (No DAC)88%
TabimorelinNo recorded rating

Sleep Quality

CJC-1295 (No DAC)92%
TabimorelinNo recorded rating

Recovery Support

CJC-1295 (No DAC)85%
TabimorelinNo recorded rating

Growth Hormone Stimulation

CJC-1295 (No DAC)No recorded rating
Tabimorelin85%

Convenience & Compliance

CJC-1295 (No DAC)No recorded rating
Tabimorelin90%

Selectivity & Safety Profile

CJC-1295 (No DAC)No recorded rating
Tabimorelin75%

Technical data

Compound specifications

CJC-1295 (No DAC)

Molecular formula
C152H252N44O42
Molecular weight
3367.9 g/mol
Half-life
30 minutes to 2 hours
Bioavailability
~100% (subcutaneous)
CAS number
863288-34-0

Tabimorelin

Molecular formula
C32H40N4O3
Molecular weight
528.7 g/mol
Half-life
Several hours (exact human half-life not published; dose-dependent pharmacokinetics)
Bioavailability
Orally active with dose-dependent bioavailability (increases at higher doses)
CAS number
193079-69-5

Protocols

Dosing compared

CJC-1295 (No DAC)

Subcutaneous

  • 100 mcgOnce daily, 30 minutes before bed · 2-4 weeksA common starting dose used in research practice. Because the no-DAC form is short-acting (about 30 minute half-life), it is injected on an empty stomach for the best growth-hormone pulse. [14][15]
  • 100 mcg per dose1-2 times daily · 8-12 weeksThe typical maintenance dose used in practice, often given before bed and/or after fasted exercise. Frequently paired with a GH-releasing peptide.
  • 100 mcg per dose2-3 times daily · 8-12 weeksA higher-frequency plan used by experienced users to mimic natural GH pulses across the day, each dose taken fasted.

Tabimorelin

Oral

  • 1.5 mg/kg per day (3 mg/kg first and last dose)Once daily · 7-day study courseDose used in GH-deficient adults (1 week course, 3 mg/kg first and last dose) [2]; significant GH release seen at 3 mg/kg and above in single-dose healthy-volunteer studies [1].

Applications

Best suited for

CJC-1295 (No DAC)

Natural Growth Hormone Optimization
Perfect for those wanting to boost their body's own GH production rather than using synthetic growth hormone. Mimics the natural pulsatile release pattern your pituitary uses [2].
Workout Recovery and Muscle Building
Athletes and fitness enthusiasts use it to accelerate recovery between training sessions, support lean muscle development, and reduce body fat over time [17] [18].
Sleep Quality Enhancement
Because GH is naturally released during deep sleep, many users report dramatically improved sleep quality with more vivid dreams and feeling more refreshed upon waking [12] [13].
Anti-Aging and Vitality
As GH levels decline with age, CJC-1295 helps restore more youthful hormone patterns, potentially improving skin quality, energy levels, and overall well-being [16] [17] [20].
Synergistic Peptide Stacking
Designed to work hand-in-hand with GHRPs like Ipamorelin. When combined, these peptides amplify each other's effects for significantly greater GH release than either alone [9].

Tabimorelin

  • Stimulates growth hormone release from the pituitary gland through ghrelin receptor activation
  • Orally active—no injections required, making it convenient for daily use
  • Dose-dependent growth hormone and IGF-1 elevation at therapeutic doses
  • Does not significantly raise ACTH, cortisol, or prolactin at most doses, showing better selectivity than some competing GH-releasing peptides
  • Well-tolerated in short-term human studies with generally mild adverse effects

Safety profile

Side effects

CJC-1295 (No DAC)

Common

  • Injection site reactions
  • Flushing or warmth
  • Water retention
  • Increased appetite

Uncommon

  • Tingling or numbness
  • Headache

Serious

  • Allergic reaction

Tabimorelin

Common

  • Headache
  • Nausea
  • Appetite stimulation
  • Dizziness
  • Dry mouth

Serious

  • Drug-drug interactions via CYP3A4 inhibition

Research status

Safety & evidence

CJC-1295 (No DAC)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
CJC-1295 without DAC itself has not been evaluated in controlled human clinical trials; expectations about its safety are extrapolated from studies of related GHRH analogs. The most common side effects are mild and include injection site reactions and temporary flushing [19]. Because it stimulates natural GH release rather than providing exogenous GH, it maintains the body's feedback mechanisms [2].

Contraindications

  • Active cancer or history of cancer
  • Pregnancy or breastfeeding
  • Pituitary tumors or disorders
  • Hypersensitivity to GHRH analogs
  • Diabetic retinopathy

Tabimorelin

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.

Contraindications

  • Active or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
  • Concurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
  • Untreated thyroid dysfunction
  • Uncontrolled diabetes

Decision guide

Which is right for you?

CJC-1295 (No DAC)

Choose CJC-1295 (No DAC) if…

  • Increasing natural growth hormone levels
  • Building lean muscle mass
  • Improving sleep quality
  • Enhancing workout recovery

Tabimorelin

Choose Tabimorelin if…

  • Stimulating growth hormone production in healthy individuals
  • Exploring GH secretagogue mechanisms in research settings
  • Patients preferring oral administration over injections